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lopidogrel and Endothelial
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oronary Interventions
eyond the Antiplatelet Effects*
oran Rudež, PHD,†
endricus J. Duckers, MD, PHD,‡
aarten L. Simoons, MD, PHD§
otterdam, the Netherlands
ual antiplatelet therapy with clopidogrel and aspirin is the
ornerstone of treatment for patients with acute coronary
yndrome and those who undergo percutaneous coronary
ntervention (PCI) (1). Clopidogrel is a thienopyridine that
electively and irreversibly inhibits the ADP receptor P2Y12,
esulting in inhibition of platelet aggregation and concom-
tant reduction of risk for secondary atherothrombotic
vents (2). Although the clinical efficacy of clopidogrel has
een proven in several large randomized clinical trials (3–5),
onsiderable interindividual heterogeneity still exists in the
esponse to this therapy (6). In approximately 5% to 30% of
lopidogrel-treated patients, the inhibition of platelet ag-
regation is insufficient (7,8). As a consequence, patients
ith high residual on-clopidogrel platelet reactivity are at a
igher risk of atherothrombotic events (6,9). Clearly,
chieving an optimal level of platelet inhibition in every
atient is of utmost importance. Or is there more to it?
See page 1024
In this issue of the Journal, Bonello et al. (10) deal with
n interesting topic on response variability to clopidogrel as
determinant of the magnitude of endothelial injury after
CI. Endothelial injury and loss of vascular integrity, in
eneral, is a crucial factor for the initiation and progression
f atherosclerosis, as well as a key trigger for atherothrom-
osis. Damage to the endothelium leads to the exposure of
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of Pharmacology, Erasmus University Medical Center,
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iology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Nether-
ands; and the §Department of Cardiology, Erasmus University Medical Center,a
otterdam, the Netherlands. All authors have reported that they have no relationships
o disclose.hrombogenic subendothelial layers and the progression of
ocal vascular inflammation. Circulating endothelial cells
CEC) are mature endothelial cells that have detached from
vascular lesion. As such, levels of CEC in peripheral blood
an serve as a biomarker of endothelial injury, which has
een suggested to have diagnostic and prognostic value in
atients with acute coronary syndrome and those undergo-
ng PCI (11). In case of PCI, stent implantation inflicts
additional) mechanical injury to the endothelium and is
haracterized by a sharp increase in levels of CEC, which is
etectable already at the end of the procedure (12,13).
reserving the endothelial integrity in the event of stent
lacement and thereafter seems to be of special importance.
Bonello et al. (10) evaluated the relationship between the
agnitude of P2Y12 receptor blockade with clopidogrel and
he amount of endothelial injury after PCI with bare metal
tent implantation. For this purpose, 149 patients with
table angina or silent ischemia were included. Specific
2Y12 receptor blockade, induced by a 600-mg loading dose
f clopidogrel, was assessed by means of a vasodilator-
timulated phosphoprotein (VASP) assay. Levels of CEC
ere measured immediately before and 6 h and 24 h after
CI. The investigators report that patients with a VASP
ndex above 50% (considered having high on-treatment
latelet reactivity) have a significantly higher rise in CEC
evels and concomitantly higher peak levels of CEC 6 h
fter PCI, compared with patients with a VASP index
elow 50% (considered good responders to clopidogrel).
verall, VASP index correlated positively with the magni-
ude of rise in CEC levels after PCI. This magnitude of
ndothelial injury appeared to be independently predicted
y the VASP group (comprised of either “good” or “bad”
esponders to clopidogrel), the number of diseased vessels,
nd the number of stents implanted. Aspirin had no effect
n the CEC levels.
Clearly, the reduction of endothelial injury after PCI is
ot the primary mechanism of action of clopidogrel but is
ather one in a row of pleiotropic effects of clopidogrel for
hich scientific evidence is emerging. In addition to platelet
nhibition (as well as the reduction of endothelial injury
eported by Bonello et al. [10]), clopidogrel has been
eported to have anti-inflammatory and vasoprotective ef-
ects. In these studies, clopidogrel treatment was associated
ith a reduction in plasma levels of the inflammatory
arker C-reactive protein (14), whereas clopidogrel treat-
ent was associated with improved systemic endothelial
itric oxide bioavailability in patients with coronary artery
isease in another study (15). Recent studies have reported
hat clopidogrel withdrawal (16), or impaired response to
lopidogrel (17), is associated with pro-thrombotic and
ro-inflammatory effects. Together, these findings suggest
hat indeed the underlying mechanism of suboptimal
lopidogrel-induced platelet inhibition on increased risk of
dverse vascular events involves not only persistent platelet
ctivation but also a proinflammatory state and an increased
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September 21, 2010:1032–3 Clopidogrel and Endothelial Injurymount of endothelial injury. However, the clinical impor-
ance of these pleiotropic effects of clopidogrel remains
nclear. Unfortunately, the prospective study by Bonello et
l. (10) does not include data on clinical outcome and
herefore does not provide an answer to this. Moreover,
iologic evidence explaining the observed associations is
acking; therefore, the question remains: does the reduction
f endothelial injury relay via platelet-mediated effects (e.g.,
he release of cytokines from platelet granulas) or does
lopidogrel somehow exert its effects on the endothelial cells
irectly? Given the improved efficacy of novel P2Y12 recep-
or antagonists, such as prasugrel and ticagrelor, that are
tarting to replace clopidogrel use in practice, it would be
nteresting to investigate whether the pleiotropic effects of
lopidogrel also relate to these novel compounds and
hether they are characterized by large interindividual
ifferences.
Interestingly, an increasing number of published reports
n the pleiotropic effects of clopidogrel has recently started
o appear. The study by Bonello et al. (10) is one of these
ut is novel regarding the association between clopidogrel
nd endothelial injury; as such, the study adds to our
nderstanding of the complex mechanisms underlying
therothrombosis and its modulation by antiplatelet phar-
acotherapy. The results of this study further suggest the
mportance of the efficacy of clopidogrel therapy for the
revention of atherothrombotic events and open a path to
ovel studies dealing with additional markers of response
o antiplatelet treatment than platelet activation and ag-
regation alone, which have been, and are still, studied
xtensively.
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